Norway· NO-ID_6FCC209D-61EB-4AA5-9845-C8B83F1EA643
Vosevi
A sofosbuvir, velpatasvir and voxilaprevir product containing sofosbuvir + velpatasvir + voxilaprevir, registered in Norway by Gilead Sciences Ireland UC. The same ATC class is registered in 13 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Sofosbuvir, velpatasvir and voxilaprevir is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AP56 (sofosbuvir, velpatasvir and voxilaprevir), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 10 of them publish a price we can compare per daily dose
Sofosbuvir, velpatasvir and voxilaprevir · ATC J05AP56
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of sofosbuvir, velpatasvir and voxilaprevir costs, country by country.
Normalised to the WHO defined daily dose (0.4 g), the median price runs from $447.39 in Switzerland to $1097.10 in Italy — a ×2.5 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Sofosbuvir, velpatasvir and voxilaprevir · price per daily dose (0.4 g)
USD · FX 28 Sept 2026
- IT Italy$1097.10
- CH Switzerland$447.39
The record
At a glance
FEST (Norway)- Active substance
- Sofosbuvir + Velpatasvir + Voxilaprevir
- Manufacturer
- Gilead Sciences Ireland UC
- Country
- Norway (NO)
- ATC code
- J05AP56
- ATC class
- Sofosbuvir, velpatasvir and voxilaprevir
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_6FCC209D-61EB-4AA5-9845-C8B83F1EA643
- no_varenummer13850528NOK 205653.5
- gtin5391507143969
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sofosbuvir, velpatasvir and voxilaprevir in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IcelandVoseviGilead Sciences Ireland UC*
- NetherlandsVosevi 200 mg/50 mg/50 mg, filmomhulde tablettenGilead Sciences Ireland UC
- PolandVoseviGilead Sciences Ireland UC
- SwedenVosevi 200 mg/50 mg/50 mg Filmdragerad tablettGilead Sciences Ireland UC
- FinlandVoseviGilead Sciences Ireland UC
- CzechiaVOSEVIGilead Sciences Ireland UC, Carrigtohill
- IrelandVosevi 200 mg/50 mg/50 mg film-coated tabletsGilead Sciences Ireland UC
- United StatesVoseviGilead Sciences, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Vosevi
- Liechtenstein · Vosevi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fd65ea99-1d1c-40bb-b5db-8e6418ff31b8 GET /v1/drugs/fd65ea99-1d1c-40bb-b5db-8e6418ff31b8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablett, filmdrasjert",
"source": "fest",
"status": "A",
"atc_name": "Sofosbuvir, velpatasvir og voksilaprevir",
"merkevare_id": "ID_6FCC209D-61EB-4AA5-9845-C8B83F1EA643",
"name_form_strength": "Vosevi tab 400 mg/100 mg/100 mg",
"prescription_group": "C"
}See everything about sofosbuvir, velpatasvir and voxilaprevir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.